拜(bai)瑪(ma)林制藥(BioMarin)宣布任(ren)命Greg Friberg醫(yi)(yi)學(xue)(xue)博(bo)(bo)士為執行(xing)副總(zong)裁(cai)(cai)(cai)兼首(shou)席(xi)研發官，接替Hank Fuchs醫(yi)(yi)學(xue)(xue)博(bo)(bo)士的職位，同時任(ren)命James Sabry醫(yi)(yi)學(xue)(xue)博(bo)(bo)士為執行(xing)副總(zong)裁(cai)(cai)(cai)兼首(shou)席(xi)商(shang)務官。Friberg醫(yi)(yi)學(xue)(xue)博(bo)(bo)士從安(an)進公司來到拜(bai)瑪(ma)林，在安(an)進他擔(dan)任(ren)罕見疾病(bing)全球醫(yi)(yi)療事(shi)務副總(zong)裁(cai)(cai)(cai)。Sabry醫(yi)(yi)學(xue)(xue)博(bo)(bo)士從羅氏/基因泰克加(jia)入拜(bai)瑪(ma)林，最近擔(dan)任(ren)羅氏合(he)作執行(xing)副總(zong)裁(cai)(cai)(cai)兼全球主管。(美通社)